Maxim Group raises its price target on Onyx from $95.00 to $105.00
Maxim Group Boosts Price Target on Onyx Pharmaceuticals (ONXX)
October 26th, 2012 - 0 comments - Filed Under - by Trevor Kearing
Filed Under: Analyst Articles - US - Stock Market
Analysts at Maxim Group upped their price target on shares of Onyx Pharmaceuticals (NASDAQ: ONXX) from $95.00 to $105.00 in a research report issued to clients and investors on Friday. The firm currently has a “buy” rating on the stock.
ONXX has been the subject of a number of other recent research reports. Analysts at Canaccord Genuity initiated coverage on shares of Onyx Pharmaceuticals in a research note to investors on Thursday, October 11th. They set a “buy” rating and a $105.00 price target on the stock. Separately, analysts at Goldman Sachs raised their price target on shares of Onyx Pharmaceuticals from $88.00 to $98.00 in a research note to investors on Friday, October 5th. They now have a “buy” rating on the stock. Finally, analysts at Bank of America reiterated a “buy” rating on shares of Onyx Pharmaceuticals in a research note to investors on Monday, October 1st. They now have a $89.00 price target on the stock.
Shares of Onyx Pharmaceuticals traded down 3.37% during mid-day trading on Friday, hitting $79.22. Onyx Pharmaceuticals has a 52 week low of $35.73 and a 52 week high of $93.18. The company has a market cap of $5.157 billion and a P/E ratio of 303.63.
Onyx Pharmaceuticals last released its earnings data on Wednesday, August 1st. The company reported ($0.68) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.69) by $0.01. The company’s quarterly revenue was up 7.0% on a year-over-year basis.